New study raises fresh concerns about Zetia and its cousin, Vytorin
A new study raises fresh concerns about Zetia and its cousin, Vytorin — drugs that are still taken by millions of Americans to lower cholesterol, despite questions raised last year about how well they work.
In the study, Zetia failed to shrink buildups in artery walls while a rival drug, Niaspan, did so significantly. Zetia users also suffered more heart attacks and other problems although the numbers of these events are too small to draw firm conclusions.
“This study provides no evidence that would reassure us that this drug is beneficial, and it provides some evidence that it may be harmful,” said Yale University cardiologist Dr. Harlan Krumholz, who had no role in the study.
»»»READ MORE«««
